Publications dans lesquelles il/elle collabore avec Maurizio Bendandi (24)

2021

  1. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2017

  1. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. MRP1-CD28 bi-specific oligonucleotide aptamers: Target costimulation to drug-resistant melanoma cancer stem cells

    Oncotarget, Vol. 7, Núm. 17, pp. 23182-23196

2015

  1. 2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia

    Biomaterials, Vol. 67, pp. 274-285

  2. Clinical safety and Immunogenicity of tumor-targeted, plant-made id-klh conjugate vaccines for follicular lymphoma

    BioMed Research International, Vol. 2015

2014

  1. Idiotype vaccine production using hybridoma technology

    Methods in Molecular Biology, Vol. 1139, pp. 367-387

2013

  1. CD28 aptamers as powerful immune response modulators

    Molecular Therapy - Nucleic Acids, Vol. 2, pp. e98

  2. Successful idiotypic vaccination following stem cell allotransplant in lymphoma

    Leukemia and Lymphoma

2011

  1. BiovaxID®: A customized idiotype vaccine for the treatment of B-cell lymphoma

    Expert Review of Vaccines, Vol. 10, Núm. 12, pp. 1661-1669

  2. Idiotype vaccines for lymphoma therapy

    Expert Review of Vaccines, Vol. 10, Núm. 6, pp. 801-809

2010

  1. Idiotype vaccines for human B-cell malignancies

    Current Pharmaceutical Design, Vol. 16, Núm. 3, pp. 300-307

  2. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma

    Annals of Oncology, Vol. 21, Núm. 12, pp. 2420-2427

2009

  1. Vacuna idiotípica en el tratamiento del linfoma folicular: situación actual y perspectivas futuras

    Anales del sistema sanitario de Navarra, Vol. 32, Núm. 1, pp. 61-73

2007

  1. Anti-idiotype antibodies in cancer treatment

    Oncogene, Vol. 26, Núm. 25, pp. 3594-3602

  2. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor

    Journal of Biological Chemistry, Vol. 282, Núm. 10, pp. 7405-7415

  3. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions

    Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies

    Haematologica, Vol. 89, Núm. 5, pp. 541-546

  2. Inmunoterapia activa en el tratamiento de neoplasias hematológicas

    Anales del sistema sanitario de Navarra, Vol. 27, Núm. 1, pp. 45-62

  3. Past, present and future of anti-idiotype vaccination

    Revista de medicina de la Universidad de Navarra, Vol. 48, Núm. 3, pp. 14-23